Jefferies raised the firm’s price target on BeOne Medicines (ONC) to $420 from $398 and keeps a Buy rating on the shares following a fireside chat and investor breakfast with management in London. The firm notes that management believes its chronic lymphocytic leukemia franchise will deliver “best-in-class” therapy to the full spectrum of CLL market. BeOne is advancing solid tumor pipeline at full speed with data in 2026, Jefferies told investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- Jazz Pharmaceuticals price target raised to $205 from $185 at Morgan Stanley
- Zymeworks’ Ziihera shows efficacy in Phase 3 adenocarcinoma trial
- BeOne Medicines reports ‘positive’ results from Phase 3 HERIZON-GEA-01 trial
- Saudi Public Investment Fund Sells Major U.S. Stocks as Portfolio Value Falls in Third Quarter
- BeOne Medicines price target raised to $405 from $399 at Citi